Capricor Therapeutics

“Behind every dataset is a patient waiting for more time, more function and more independence.” – Dr. Linda Marbán, Capricor CEO Today's FDA Advisory Committee meeting is underway. Watch live: youtube.com/live/SUNn6YcBh…

We're pleased to share that @TheLancet has published results from Capricor's Phase 3 HOPE-3 trial evaluating Deramiocel in #Duchenne muscular dystrophy. The independent peer-reviewed publication validates the trial's design, statistical methodology and findings. HOPE-3 met its primary endpoint, with Deramiocel slowing upper limb function decline by 54 percent versus placebo (PUL 2.0, p=0.03) and demonstrating a clinically meaningful cardiac benefit. Read more here: thelancet.com/journals/lance… We are grateful to the patients, families, investigators and study teams who made this research possible.

Capricor's FDA Advisory Committee meeting will be livestreamed tomorrow, July 29, from 9:30 a.m. to 5 p.m. EST. We invite shareholders, analysts, partners and the broader DMD community to tune in here: lnkd.in/gdv7tqhM Thank you for your continued support.

Capricor has shared its comments regarding the FDA briefing materials in advance of the upcoming July 29 FDA Advisory Committee Meeting for Deramiocel. $CAPR #deramiocel #DMD Click the link below to read the press release.>>> bit.ly/4vRqq96

Today, our CEO, Linda Marbán, presented at the Oppenheimer CNS & NeuroMuscular Summit in Miami, Florida, alongside leaders from Sarepta and Dyne during the “Advancing Duchenne: Perspectives From Industry Leaders” panel. Proud to be part of the important conversations shaping the future of Duchenne muscular dystrophy treatment and innovation.

Capricor will be participating in two investor conferences this week in Miami — the Goldman Sachs 47th Annual Global Healthcare Conference (fireside chat, June 10 at 10:00 a.m. ET) and the Oppenheimer CNS and Neuro-Muscular Summit. To view the Goldman Sachs webcast, click here. bit.ly/3POYzHT $CAPR #DMD #Deramiocel

We are pleased to welcome Michael Maurer to Capricor as our Chief Commercial Officer. With more than two decades of rare disease commercialization experience across neuromuscular disorders, neuroscience, and immunology, Michael's deep expertise bringing complex therapies to patients further strengthens our team as we prepare for the potential launch of Deramiocel for Duchenne muscular dystrophy and work toward our August 22 PDUFA date. Click here to read the announcement bit.ly/3RFEyUw $CAPR #DMD #Duchenne #Deramiocel

Capricor is presenting today at the CureDuchenne FUTURES Conference in Orlando, FL. Join us during the Science Main Stage Session: Preserving, Protecting, & Regenerating Muscle from 11:00 AM – 12:30 PM ET. View the full conference agenda here: web.cvent.com/event/ee9e7402… $CAPR #DMD #CureDuchenne #Deramiocel

Capricor is proud to be presenting our HOPE-3 results at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting being held this week in Boston (May 11–15). With over 2,000 abstracts showcasing the latest in cell and gene therapy, this is one of the premier gatherings in the industry — and we look forward to sharing our data. Click to see the full conference agenda: annualmeeting.asgct.org/program-worksh… #ASGCT2026 #DMD #HOPE3 $CAPR #Deramiocel

Capricor just reported its first quarter 2026 financial results and provided a recent corporate update. Click here to read the full release: bit.ly/4udKQcy $CAPR #DMD #Deramiocel

Capricor will report its first quarter 2026 financial results and provide a recent corporate update on May 12 at 4:30 p.m. ET. Register for the webcast to stay up to date on our progress and key developments: bit.ly/3P1v5Ww $CAPR #Deramiocel #DMD

At the American Academy of Neurology (AAN) 2026 Annual Meeting in Chicago, Capricor will be presenting Phase 3 HOPE-3 results for Deramiocel in a late-breaking oral presentation later today. The presentation highlights previously reported topline data demonstrating significant functional benefits in patients with Duchenne muscular dystrophy (DMD). For more information, please click bit.ly/4cXjCAt $CAPR #Deramiocel #DMD #AANAM #Duchenne

Capricor is pleased to be attending the 38th Annual Roth Conference this week in Dana Point, California. The annual conference brings together more than 400 public and private companies, along with investors, for expert-led panels and keynotes across a range of multiple sectors. #ROTHConference $CAPR

We just reported our fourth quarter and full year 2025 financial results. Click here to read the release: bit.ly/4bKdCcP Our quarterly conference call begins at 4:30 p.m. ET – join the webcast here: bit.ly/3NjKRLy $CAPR #DMD #Deramiocel

Yesterday at #MDA2026, we presented late-breaking data from the Phase 3 HOPE-3 trial highlighting Deramiocel’s potential impact on functional outcomes in Duchenne muscular dystrophy. Read the full release: bit.ly/3NfTTcE $CAPR #DMD #Deramiocel

We’re pleased to be attending the 2026 MDA Conference this week in Orlando, Florida. This important meeting brings together clinicians, researchers and patient advocates to discuss the latest developments in Duchenne muscular dystrophy (DMD) and other neuromuscular diseases. Capricor will be featured in the late-breaking presentation on March 11 and will also be at Booth #407 during the meeting. If you’re attending, please stop by and say hello. #MDA2026 $CAPR #MuscularDystrophy #DMD #Deramiocel

Today we announced that the U.S. FDA has resumed review of our BLA for Deramiocel for the treatment of Duchenne muscular dystrophy and set a PDUFA target action date of August 22, 2026. Click here to read the announcement: bit.ly/4bz2qk2 #DMD #Deramiocel $CAPR